{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:35:28Z","timestamp":1793241328045,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11030-022-10406-8","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T14:02:40Z","timestamp":1646229760000},"page":"2981-3002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0071-6570","authenticated-orcid":false,"given":"Pezhman","family":"Shiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorour","family":"Ramezanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Mohammad","family":"Amani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-0629","authenticated-orcid":false,"given":"Wim","family":"Dehaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"10406_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9944214","author":"V Mohammadkarimi","year":"2021","unstructured":"Mohammadkarimi V, Azarpira N, Ghanbarinasab Z, Shiri P, Dehghani FS, Nakhostin-Ansari A, Tayyebi-Khorrami F, Atapour A, Amani AM (2021) Synthesis of silver-doxycycline complex nanoparticles and their biological evaluation on MCF-7 cell line of the breast cancer. J Chem. https:\/\/doi.org\/10.1155\/2021\/9944214","journal-title":"J Chem"},{"issue":"46","key":"10406_CR2","first-page":"13459","volume":"4","author":"K Mashayekh","year":"2019","unstructured":"Mashayekh K, Shiri P (2019) An overview of recent advances in the applications of click chemistry in the synthesis of bioconjugates with anticancer activities. Chem Sel 4(46):13459\u201313478","journal-title":"Chem Sel"},{"issue":"1","key":"10406_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/03602532.2019.1582661","volume":"51","author":"SM Mousavi","year":"2019","unstructured":"Mousavi SM, Soroshnia S, Hashemi SA, Babapoor A, Ghasemi Y, Savardashtaki A, Amani AM (2019) Graphene nano-ribbon based high potential and efficiency for DNA, cancer therapy and drug delivery applications. Drug Metab Rev 51(1):91\u2013104","journal-title":"Drug Metab Rev"},{"key":"10406_CR4","doi-asserted-by":"publisher","first-page":"117060","DOI":"10.1016\/j.lfs.2019.117060","volume":"239","author":"N Korgaonkar","year":"2019","unstructured":"Korgaonkar N, Yadav KS (2019) Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy. Life Sci 239:117060","journal-title":"Life Sci"},{"issue":"5","key":"10406_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"key":"10406_CR6","first-page":"321","volume":"18","author":"DE Szollosi","year":"2019","unstructured":"Szollosi DE, Kinney SR, Amin AR, Chumbow N (2019) 10 Cancer Immunotherapy. Pharmacol Immunother Drugs 18:321","journal-title":"Pharmacol Immunother Drugs"},{"issue":"13","key":"10406_CR7","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1142\/S0218202514500304","volume":"24","author":"EA Lima","year":"2014","unstructured":"Lima EA, Oden JT, Almeida RC (2014) A hybrid ten-species phase-field model of tumor growth. Math Model Methods Appl Sci 24(13):2569\u20132599","journal-title":"Math Model Methods Appl Sci"},{"issue":"10","key":"10406_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/avj.12747","volume":"96","author":"KA Mander","year":"2018","unstructured":"Mander KA, Finnie JW (2018) Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. Aust Vet J 96(10):371\u2013378","journal-title":"Aust Vet J"},{"issue":"6","key":"10406_CR9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3748\/wjg.v9.i6.1144","volume":"9","author":"MK Gupta","year":"2003","unstructured":"Gupta MK, Qin RY (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol WJG 9(6):1144","journal-title":"World J Gastroenterol WJG"},{"issue":"24","key":"10406_CR10","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1039\/C7LC00774D","volume":"17","author":"LJ Chen","year":"2017","unstructured":"Chen LJ, Kaji H (2017) Modeling angiogenesis with micro-and nanotechnology. Lab Chip 17(24):4186\u20134219","journal-title":"Lab Chip"},{"issue":"1","key":"10406_CR11","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1038\/sj.gt.3302621","volume":"12","author":"M Malecki","year":"2005","unstructured":"Malecki M, Kolsut P, Proczka R (2005) Angiogenic and antiangiogenic gene therapy. Gene Ther 12(1):S159\u2013S169","journal-title":"Gene Ther"},{"issue":"1","key":"10406_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K (2019) Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 12(1):1","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10406_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbapap.2003.11.010","volume":"1697","author":"PW Manley","year":"2004","unstructured":"Manley PW, Bold G, Br\u00fcggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim et Biophys Acta Proteins Proteomics 1697(12):17\u201327","journal-title":"Biochim et Biophys Acta Proteins Proteomics"},{"issue":"1","key":"10406_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9\u201322","journal-title":"FASEB J"},{"issue":"12","key":"10406_CR15","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1093\/humrep\/det337","volume":"28","author":"TE Fisher","year":"2013","unstructured":"Fisher TE, Molskness TA, Villeda A, Zelinski MB, Stouffer RL, Xu J (2013) Vascular endothelial growth factor and angiopoietin production by primate follicles during culture is a function of growth rate, gonadotrophin exposure and oxygen milieu. Hum Reprod 28(12):3263\u20133270","journal-title":"Hum Reprod"},{"issue":"18","key":"10406_CR16","doi-asserted-by":"publisher","first-page":"9850","DOI":"10.1073\/pnas.93.18.9850","volume":"93","author":"PM Smallwood","year":"1996","unstructured":"Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry SH, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J (1996) Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci 93(18):9850\u20139857","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10406_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0306-3623(96)00060-2","volume":"27","author":"AD Hughes","year":"1996","unstructured":"Hughes AD, Clunn GF, Refson J, Demoliou-Mason C (1996) Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gener Pharmacol Vasc Syst 27(7):1079\u20131089","journal-title":"Gener Pharmacol Vasc Syst"},{"issue":"1","key":"10406_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1568009619666191114110359","volume":"20","author":"F Gao","year":"2020","unstructured":"Gao F, Yang C (2020) Anti-VEGF\/VEGFR2 monoclonal antibodies and their combinations with PD-1\/PD-L1 inhibitors in clinic. Curr Cancer Drug Targets 20(1):3\u201318","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"10406_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1677\/erc.0.0080161","volume":"8","author":"E Zwick","year":"2001","unstructured":"Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr-Relat Cancer 8(3):161\u2013173","journal-title":"Endocr-Relat Cancer"},{"key":"10406_CR20","doi-asserted-by":"publisher","first-page":"175883592091530","DOI":"10.1177\/1758835920915303","volume":"12","author":"M Bersanelli","year":"2020","unstructured":"Bersanelli M, Brunelli M, Gnetti L, Maestroni U, Buti S (2020) Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Ther Adv Med Oncol 12:1758835920915303","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10406_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jjco\/hyy053","volume":"48","author":"S Miyamoto","year":"2018","unstructured":"Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A (2018) Drug review: pazopanib. Jpn J Clin Oncol 48(6):503\u2013513","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10406_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/1078155220950440","volume":"27","author":"M Fanelli","year":"2021","unstructured":"Fanelli M, Caputo F, Cerma K, Gelsomino F, Bari A, Dominici M, Pozzi S (2021) Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: a case report and review of the literature. J Oncol Pharm Pract 27(3):766\u2013770","journal-title":"J Oncol Pharm Pract"},{"key":"10406_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3389\/fonc.2020.01228","volume":"10","author":"I Russo","year":"2020","unstructured":"Russo I, Di Paolo V, Crocoli A, Mastronuzzi A, Serra A, Di Paolo PL, Di Giannatale A, Miele E, Milano GM (2020) A chart review on the feasibility and safety of the vincristine irinotecan pazopanib (VIPaz) association in children and adolescents with resistant or relapsed sarcomas. Front Oncol 10:1228","journal-title":"Front Oncol"},{"issue":"1","key":"10406_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/cancers12010036","volume":"12","author":"A Facciorusso","year":"2020","unstructured":"Facciorusso A, Abd El Aziz MA, Sacco R (2020) Efficacy of regorafenib in hepatocellular carcinoma patients: a systematic review and meta-analysis. Cancers 12(1):36","journal-title":"Cancers"},{"issue":"2","key":"10406_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clcc.2017.10.016","volume":"17","author":"AB Abrahao","year":"2018","unstructured":"Abrahao AB, Ko YJ, Berry S, Chan KK (2018) A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. Clin Colorectal Cancer 17(2):113\u2013120","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"10406_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40265-018-0938-y","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Regorafenib: a review in metastatic colorectal cancer. Drugs 78(11):1133\u20131144","journal-title":"Drugs"},{"key":"10406_CR27","doi-asserted-by":"publisher","first-page":"175883592094093","DOI":"10.1177\/1758835920940932","volume":"12","author":"Y Wu","year":"2020","unstructured":"Wu Y, Fan Y, Dong D, Dong X, Hu Y, Shi Y, Jing J, Li E (2020) Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review. Ther Adv Med Oncol 12:1758835920940932","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10406_CR28","doi-asserted-by":"publisher","first-page":"107327481878936","DOI":"10.1177\/1073274818789361","volume":"25","author":"K Suyama","year":"2018","unstructured":"Suyama K, Iwase H (2018) Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control 25(1):1073274818789361","journal-title":"Cancer Control"},{"issue":"6","key":"10406_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ (2019) Lenvatinib: a review in hepatocellular carcinoma. Drugs 79(6):665\u2013674","journal-title":"Drugs"},{"key":"10406_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103366","author":"S Fogli","year":"2021","unstructured":"Fogli S, Gianfilippo G, Cucchiara F, Del Re M, Valerio L, Elisei R, Danesi R (2021) Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103366","journal-title":"Crit Rev Oncol Hematol"},{"key":"10406_CR31","doi-asserted-by":"publisher","first-page":"109573","DOI":"10.1016\/j.cellsig.2020.109573","volume":"70","author":"JL Roberts","year":"2020","unstructured":"Roberts JL, Poklepovic A, Booth L, Dent P (2020) The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. Cell Signal 70:109573","journal-title":"Cell Signal"},{"key":"10406_CR32","unstructured":"Lizeng P, Longfei M, Xiaofei L; Xiaojun Y, Huanxiang L, Qifeng B, Lixian L (2019) Green preparation method of pazopanibhydrochloride. CN110028495, A"},{"issue":"4","key":"10406_CR33","first-page":"443","volume":"71","author":"SV Keisner","year":"2011","unstructured":"Keisner SV, Shah SR (2011) Pazopanib. Drugs 71(4):443\u2013454","journal-title":"Drugs"},{"key":"10406_CR34","unstructured":"Haidong L, Min J, Xi Z, Dongdong W, Su Y, Guangpeng W, Wenyuan Y, Haiyan H, Ying Z (2018) Preparation method and intermediate of pazopanib. CN107721989, A"},{"key":"10406_CR35","unstructured":"Kumar R, Giri P, Barman DC, Nath A, Prasad M (2015) Process for the preparation of pazopanib or salts thereof. US2015\/329526, A1"},{"issue":"1","key":"10406_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-11089-w","volume":"21","author":"VL Purushothaman","year":"2021","unstructured":"Purushothaman VL, Cuomo RE, Garland CF, Mackey TK (2021) Could age increase the strength of inverse association between ultraviolet B exposure and colorectal cancer? BMC Public Health 21(1):1\u20139","journal-title":"BMC Public Health"},{"issue":"6","key":"10406_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/13543784.2012.684752","volume":"21","author":"D Strumberg","year":"2012","unstructured":"Strumberg D, Schultheis B (2012) Regorafenib for cancer. Expert Opin Investing drugs 21(6):879\u2013889","journal-title":"Expert Opin Investing drugs"},{"key":"10406_CR38","doi-asserted-by":"publisher","first-page":"101912","DOI":"10.1016\/j.ctrv.2019.101912","volume":"81","author":"H Arai","year":"2019","unstructured":"Arai H, Battaglin F, Wang J, Lo JH, Soni S, Zhang W, Lenz HJ (2019) Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev 81:101912","journal-title":"Cancer Treat Rev"},{"key":"10406_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/CMAR.S88825","volume":"10","author":"G Goel","year":"2018","unstructured":"Goel G (2018) Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a \u201cme too\u201d drug? Cancer Manag Res 10:425","journal-title":"Cancer Manag Res"},{"key":"10406_CR40","unstructured":"Qiang X, Shuang H, Jian Y, Ping W, Bin X, Gang Q (2015) Regorafenib preparation method. CN105130887A"},{"key":"10406_CR41","unstructured":"Song S, Qiang L, Xiaolong H (2016) Preparation method for regorafenib hydrate. CN105330600A"},{"key":"10406_CR42","unstructured":"Zhenteng L, Xinquan L, Shuhong W, Ruizhao G (2018) Preparation method of regorafenib. CN108558747A"},{"key":"10406_CR43","unstructured":"Zhenteng L, Junkai H, Xuezhen F, Taotao Y (2018) Preparation method of regorafenib compound. CN108329260A"},{"key":"10406_CR44","unstructured":"Zhenteng L, Guichao X, Huihui M, Bingpeng G (2018) A kind of preparation method of regorafenib. CN108440403"},{"key":"10406_CR45","unstructured":"Zhenteng L, Lili S, Zhicheng C (2018) Preparation method of regorafenib. CN108997209B"},{"key":"10406_CR46","unstructured":"Ping G, Xin Z, Yanfang Z, Yajing L, Limei W, Qianru Y (2014) A kind of preparation method of regorafenib. CN105566215B"},{"issue":"6","key":"10406_CR47","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ijms18061292","volume":"18","author":"B Schmidbauer","year":"2017","unstructured":"Schmidbauer B, Menhart K, Hellwig D, Grosse J (2017) Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci 18(6):1292","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10406_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","volume":"46","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Takahashi S (2019) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 46(1):57\u201364","journal-title":"Semin Oncol"},{"issue":"2","key":"10406_CR49","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12020-020-02418-x","volume":"70","author":"A Campenn\u00ec","year":"2020","unstructured":"Campenn\u00ec A, Barbaro D, Guzzo M, Capoccetti F, Giovanella L (2020) Personalized management of differentiated thyroid cancer in real life\u2013practical guidance from a multidisciplinary panel of experts. Endocrine 70(2):280\u2013291","journal-title":"Endocrine"},{"key":"10406_CR50","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fonc.2017.00238","volume":"7","author":"SR Priya","year":"2017","unstructured":"Priya SR, Dravid CS, Digumarti R, Dandekar M (2017) Targeted therapy for medullary thyroid cancer: a review. Front Oncol 7:238","journal-title":"Front Oncol"},{"issue":"2","key":"10406_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/EJE-19-0763","volume":"182","author":"MD Aydemirli","year":"2020","unstructured":"Aydemirli MD, Kapiteijn E, Ferrier KR, Ottevanger PB, Links TP, van der Horst-Schrivers AN, Broekman KE, Groenwold RH, Zwaveling J (2020) Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur J Endocrinol 182(2):131\u2013138","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10406_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11523-015-0416-3","volume":"11","author":"JE Frampton","year":"2016","unstructured":"Frampton JE (2016) Lenvatinib: a review in refractory thyroid cancer. Target Oncol 11(1):115\u2013122","journal-title":"Target Oncol"},{"key":"10406_CR53","doi-asserted-by":"crossref","unstructured":"Zsch\u00e4bitz S, Gr\u00fcllich C (2018) Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET. Small Molecules in Oncology. 187\u2013198.","DOI":"10.1007\/978-3-319-91442-8_13"},{"key":"10406_CR54","unstructured":"Naito T, Naito T, Yoshizawa K, Yoshizawa K (2004) Urea derivative and method for producing the same. JPWO2005044788A1"},{"key":"10406_CR55","unstructured":"Huijuan J, Yan C, Fan Z, Xuemin H (2016) Preparation methods of lenvatinib mesylate drug impurities. CN107266363A"},{"key":"10406_CR56","unstructured":"Nakamura T, Abe T, Yusuke Miyashita Y, Kuroda H, Yusuke K, Yusuke A, Atsushi A (2016) High purity quinoline derivative and method for producing the same. JPWO2016031841A1"},{"key":"10406_CR57","unstructured":"Xingmin L (2016) A kind of synthetic method of lenvatinib. CN105801481A"},{"key":"10406_CR58","unstructured":"Shiyang Z, Yonggang Z (2017) Synthesis method for lenvatinib. CN108658859A"},{"key":"10406_CR59","unstructured":"Lichun D, Geng H, Qi L, Dianqing L, Haoyuan W (2017) Synthetic method of anti-cancer drug lenvatinib. CN107629001A"},{"key":"10406_CR60","unstructured":"Peng H, Xuechao W, Dunta, Qian H (2018) Lenvatinib intermediate, preparation thereof and preparation of lenvatinib. CN108997214A"},{"key":"10406_CR61","unstructured":"Dharmesh Mahendrabhai S, Guruprasad Ramchandra W, Tushar Bharatkumar M, Rajendra Gokalbhai C, Harshad Ghanshyambhai K, Arpit Kiritbhai P (2019) An improved process for the preparation of lenvatinib. WO2019016664A1"},{"key":"10406_CR62","unstructured":"Xueping W, Yao C (2018) Method for synthesizing lenvatinib. CN109456267A"},{"key":"10406_CR63","unstructured":"Srinivasan TR, Sajja E, Gogulapati VPR, Sagam RR, Bandla PKR, Rangineni S (2019) Novel polymorphs of 4-[3-chloro-4-(n'-cyclopropyl ureido)phenoxy]-7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof. WO2019111283A1"},{"key":"10406_CR64","unstructured":"Yong Z, Zhantao Z, Station Y, Zhenggao S, Chuanwen F, Dong L (2019) Preparation method of high-purity Levatinib mesylate crystal form C. CN111689897A"},{"key":"10406_CR65","unstructured":"Chen M, Zhang Y, Diao X, Zhang X (2016) New crystal form of lenvatinib methanesulfonate salt and preparation method thereof. EP3287444A1"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-022-10406-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T12:10:32Z","timestamp":1664885432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-022-10406-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10406"],"URL":"https:\/\/doi.org\/10.1007\/s11030-022-10406-8","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}